Despite regulatory uncertainty around the US Food and Drug Administration’s Diversity Action Plans (DAPs), most trial sponsors remain firmly committed to building more representative studies.
The missing piece has not been intent; it has been the operational tools to act on it at scale.
AI and real-world data (RWD) are now providing exactly that. Clinical trial diversity has long sat at the intersection of scientific necessity, ethical obligation and commercial pragmatism.
Check out the rest of the feature here
